Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anlotinib + Docetaxel in advanced NSCLC
NCT03732001Phase 2Unknown
- Sponsor
- China Medical University
- Start
- Nov 2018
- Primary completion
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of anlotinib in non-small cell lung cancer (NSCLC), sponsored by China Medical University. Primary endpoint: Progression-Free Survival at 24 months. Status: unknown.
02
Drugs
anlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03732001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03732001.